Search

Elecsys® β-Amyloid(1-42) CSF II

Robust and accurate biomarker tests to solve clinical questions

Elecsys® β-Amyloid(1-42) CSF II
Robust and accurate biomarker tests to solve clinical questions

Elecsys® β-Amyloid(1-42) CSF II (AB42 2) is an in vitro diagnostic immunoassay intended for the quantitative determination of the β-Amyloid(1-42) protein concentration in human cerebrospinal fluid (CSF).1

Elecsys® AB42 2 assay is part of the Elecsys® AD portfolio, along with Elecsys® Phospho-Tau (181P) CSF (pTau) and Elecsys® Total-Tau CSF (tTau) immunoassays.1

Elecsys® AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.2,3

Elecsys® AD CSF assays enable timely intervention by identifying patients with MCI at risk of progression to AD.1,3

Related portfolios

Related Instruments

Contact Us
HCPs at computer

The Power of Elecsys® in Alzheimer’s disease

Robust, clinically validated results to help ensure patients get the care they deserve

Elecsys® β-Amyloid(1-42) CSF II

  • Testing time

    18 minutes

  • Test principle

    Two-step sandwich 

  • Calibration

    2-point

  • Sample material

    Cerebrospinal Fluid (CSF)

  • Sample volume

    30 µL - cobas e 801 module and cobas e 402 module 

    50 µL - cobas e 411 analyzer and cobas e 601/602 modules

  • LoB (Limit of Blank)

    50 pg/mL

  • LoD (Limit of Detection)

    100 pg/mL

  • LoQ (Limit of Quantitation)

    150 pg/mL

  • Measuring range

    150 – 2,500 pg/mL

  • Reagent onboard-stability

    16 days - cobas e 801 module and cobas e 402 module

    28 weeks - cobas e 411 analyzer and cobas e 601/602 modules

You might be interested in

...
    ...

    References

    1. Elecsys® Method Sheet: ms_08821941500V1.0, ms_08821909500V1.0, ms_08846715500V1.0, ms_08846693500V1.0,  ms_08846634500V1.0, ms_08846685500V1.0
    2. Rabinovici, G.D. et al. (2019). Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 321(13), 1286-1294.
    3. Hansson, O. et al. (2018). CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14(11), 1470-1481
    Elecsys® Total -Tau CSF
    Elecsys® Total -Tau CSF
    Elecsys® Phospho-Tau (181P) CSF
    Elecsys® Phospho-Tau (181P) CSF